skip to primary navigationskip to content

Cambridge Institute for Medical Research

Department A-Z

Our strategy

We aim to create an inspiring environment in which outstanding scientists can excel. By providing state-of-the-art core facilities and support for our researchers, we foster new collaborations that spark discoveries about fundamental cellular processes and their relevance in disease.

Read more

Cambridge Science Festival

Only a few weeks until the Cambridge Science Festival kicks off (March 13-26). Join our researchers for hands-on activities at the Guildhall and Biomedical Campus.

Read more

Research advances

The Buss lab report in PNAS that reversing the directionality of myosin VI movement on actin triggers reorganization of cortical actin coupled to clustering of endosomes.

Read more

Call for new investigators

The Cambridge Institute for Medical Research (CIMR) seeks to recruit exceptional researchers at all career stages.

Read more

Potential haemophilia treatment

£14 million Series A funding has been secured for ApcinteX Limited, a spin-out arising from a collaboration between Jim Huntington (CIMR) and Trevor Baglin (Addenbrooke's) to develop a new treatment for haemophilia.

Read more

Research news

A collaboration between the lab of Lucy Raymond, UCL Great Ormond Street Institute of Child Health and the NIHR Rare Disease Bioresource has identified a new genetic movement disorder (KMT2B-related dystonia) that can be treated with deep brain stimulation.

Read more

A unique partnership between basic and clinical research, aiming to understand the cellular basis of disease

New publications


Buss lab (J. Cell Sci. 2017)

Myosin VI function at cardiomyocyte gap junctions.


Raymond lab (Nature Genet. 2016)

Identification of a KMT2B-linked movement disorder.


Rubinsztein lab (Nature Comm. 2016)

Chaperone inhibition of protein aggregation via autophagy.


Ron lab (Nature Struct. Mol. Biol. 2016)

FICD-mediated de-AMPylation of BiP ER chaperone.


Huntington lab (Blood 2016)

Engineered serpins for rescue of thrombin generation.


Lehner lab (eLife 2016)

Vif targeting of PP2A in HIV infection.